Abstract
Background
As the survival rates of patients with renal cell carcinoma (RCC) continue to increase, noncancer causes of death cannot be ignored. The cause-specific mortality in patients with RCC is not well understood.
Objective
Our study aimed to explore the mortality patterns of contemporary RCC survivors.
Methods
We performed a retrospective cohort study involving patients with RCC from the Surveillance, Epidemiology, and End Results (SEER) database. We used standardized mortality ratios (SMRs) to compare the death rates in patients with RCC with those in the general population.
Results
A total of 106,118 patients with RCC, including 39,630 who died (27%), were included in our study. Overall, compared with the general US population, noncancer SMRs were increased 1.25-fold (95% confidence intervals [CI], 1.22 to 1.27; observed, 11,235), 1.19-fold (95% CI, 1.14 to 1.24; observed, 2,014), and 2.24-fold (95% CI, 2.11 to 2.38; observed, 1,110) for stage I/II, III, and IV RCC, respectively. The proportion of noncancer causes of death increased with the extension of survival time. A total of 4,273 men with stage I/II disease (23.13%) died of RCC; however, patients who died from other causes were 3.2 times more likely to die from RCC (n = 14,203 [76.87%]). Heart disease was the most common noncancer cause of death (n = 3,718 [20.12%]; SMR, 1.23; 95% CI, 1.19–1.27). In patients with stage III disease, 3,912 (25.98%) died from RCC, and 2,014 (13.37%) died from noncancer causes. Most patients (94.99%) with stage IV RCC died within 5 years of initial diagnosis. Although RCC was the leading cause of death (n = 12,310 [84.65%]), patients with stage IV RCC also had a higher risk of noncancer death than the general population (2.24; 95% CI, 2.11–2.38).
Conclusions
Non-RCC death causes account for more than 3/4 of RCC survivors among patients with stage I/II disease. Patients with stage IV are most likely to die of RCC; however, there is an increased risk of dying from septicemia, and suicide cannot be ignored. These data provide the latest and most comprehensive assessment of the causes of death in patients with RCC.
Keywords: cause of death, renal cell cancer, standardized mortality ratios (SMRs), noncancer cause of death, Surveillance, Epidemiology, and End Results (SEER)
Introduction
Renal cell carcinoma (RCC) is one of the top 10 most prevalent cancers and accounts for 4% of all new malignancies in the United States (U.S.) (1, 2). Approximately 1.7% of people are diagnosed with kidney cancer at some point in their lives (1, 2). As treatment has improved, the death rate from kidney cancer has decreased. It is estimated that there will be 793,530 cancer survivors in the U.S. by 2030 (1–3). Therefore, understanding the real causes of death could help prioritize death risk during survivorship and may provide a roadmap for reducing the mortality burden after RCC.
The causes of death from prostate cancer, colon cancer, testicular cancer, and other cancers have been well described (4–9). Several studies have described the causes of death in patients with RCC. However, these studies were not compared with the risk in the general population, either based on small sample studies, or limited to secondary primary tumors, and the classification of the cause of death is not detailed enough (10–12). To address these limitations, we assessed contemporary, population-based data on the causes of death during RCC survivorship. We present our results based on patient characteristics and the AJCC 6th stage, and the risk of death from each cause was compared with that of the standard population.
Materials and Methods
Data Source
This was a retrospective, observational, cohort study. We used data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) 18 registries, November 2020 submission (2000 to 2018) for SMRs, which covers approximately 34.6% of the U.S. population.
Patients
We included all patients diagnosed with RCC as their first malignant tumor between January 1, 2004, and December 31, 2015. Patients with an unknown follow-up time, vital status, and staging information (I, II, III, or IV) were excluded. We excluded patients diagnosed through autopsy or death certificates only. Figure 1 shows the inclusion and exclusion criteria of the present study.
Figure 1.
Flowchart of participant selection.
Exposures for Stratification
We included the following covariates: stage of disease based on the derived AJCC stage group, 6th ed (I/II vs. III vs. IV;), sex (male or female), age (<65 or ≥65 years old), race (white, black, or other), year of diagnosis (2004–2007, 2008–2011, or 2012–2015), histology type (clear cell, papillary, chromophobe, or other), surgery (yes or no), radiation (yes or no), chemotherapy (yes or no), and marital status (married, never married, or other).
Outcome Assessments
The outcome variable of interest was overall survival after RCC diagnosis. The SEER cause of death code was based on the International Statistical Classification of Diseases and Related Health Problems 10th, 1999 (ICD‐10).
Ethics Statement
We were granted permission from the National Cancer Institute USA to access the SEER dataset for research purposes only (reference number: 20025-Nov2020). All data from the SEER database were de-identified, and the extracted data did not require informed consent.
Statistical Analyses
We used standardized mortality ratios (SMRs), defined as the observed number of deaths divided by the expected number. The expected numbers of deaths were calculated based on age- and sex-specific mortality rates in a standard population. The follow-up time began from the date of first diagnosis to the date of death, loss to follow-up (date of the last visit), or December 2018, whichever came first. The 95% confidence intervals (CIs) for SMRs were estimated using exact methods. All SMRs were generated using the SEER*Stat version 8.3.9.2.
Results
Baseline Characteristics
Of the 106,118 patients with RCC, 39,630 (37.35%) died. The median follow-up duration was 68 months (Q1–Q3, 38–109 months). The number of male patients (n = 67,020 [63.16%]) was 1.71 times higher than that of female patients (n = 39,098 [36.84%]). Most patients (n = 74,733 [70.42%]) had stage I/II disease, whereas only 14.19% (n = 15,058) and 15.39% (n = 16,327) had stage III and IV disease, respectively. The majority of the patients (n = 83,132 [78.34%]) had clear cell histology type, and 87,350 (82.31%) were white. Most patients received cancer-directed surgery (n = 91,742 [86.45%]). The basic characteristics of the patients with RCC and the number of deaths at different follow-up times are shown in Table 1.
Table 1.
Patient characteristics and death by time after diagnosis.
| Stage | Group | All patients Diagnosed With RCC, No. | Timing of Death After Diagnosis, No. (%) | ||||
|---|---|---|---|---|---|---|---|
| All Years | <1 year | 1 to <5 years | 5 to <10 years | ≥10 years | |||
| All | Stage | ||||||
| I/II | 74,733 (70.4%) | 18,476 (46.62%) | 2,164 (17.87%) | 8,106 (48.86%) | 6,402 (73.80%) | 1,804 (80.04%) | |
| III | 15,058 (14.2%) | 6,612 (16.68%) | 1,224 (10.11%) | 3,378 (20.36%) | 1,648 (19.00%) | 362 (16.06%) | |
| IV | 16,327 (15.4%) | 14,542 (36.69%) | 8,724 (72.03%) | 5,105 (30.77%) | 625 (7.20%) | 88 (3.90%) | |
| I/II | Sex | ||||||
| Male | 45,641 (61.07%) | 11,676 (63.20%) | 1,352 (62.48%) | 51,89 (64.01%) | 4,017 (62.75%) | 1,118 (61.97%) | |
| Female | 28,859 (38.62%) | 6,800 (36.80%) | 812 (37.52%) | 2,917 (35.99%) | 2,385 (37.25%) | 686 (38.03%) | |
| Age, years | |||||||
| <65 | 45,874 (61.38%) | 6,766 (36.62%) | 629 (29.07%) | 2,976 (36.71%) | 2,402 (37.52%) | 759 (42.07%) | |
| ≥65 | 28,859 (38.62%) | 11,710 (63.38%) | 1,535 (70.93%) | 5,130 (63.29%) | 4,000 (62.48%) | 1,045 (57.93%) | |
| Race | |||||||
| White | 60,931 (81.53%) | 15,005 (81.21%) | 1,711 (79.07%) | 6,547 (80.77%) | 5,281 (82.49%) | 1,466 (81.26%) | |
| Black | 9,421 (12.61%) | 2,570 (13.91%) | 344 (15.90%) | 1,173 (14.47%) | 820 (12.81%) | 233 (12.92%) | |
| Other | 4,381 (5.86%) | 901 (4.88%) | 109 (5.04%) | 386 (4.76%) | 301 (4.70%) | 105 (5.82%) | |
| Marital status | |||||||
| Married | 45,378 (60.72%) | 9,864 (53.39%) | 985 (45.52%) | 4,191 (51.70%) | 3,611 (56.40%) | 1,077 (59.70%) | |
| Never married | 11,458 (15.33%) | 2,505 (13.56%) | 332 (15.34%) | 1,172 (14.46%) | 773 (12.07%) | 228 (12.64%) | |
| Other | 17,897 (23.95%) | 6,107 (33.05%) | 847 (39.14%) | 2,743 (33.84%) | 2,018 (31.52%) | 499 (27.66%) | |
| Surgery | |||||||
| Yes | 69,766 (93.35%) | 15,433 (83.53%) | 1,274 (58.87%) | 6,544 (80.73%) | 5,884 (91.91%) | 1,731 (95.95%) | |
| No | 4,967 (6.65%) | 3,043 (16.47%) | 890 (41.13%) | 1,562 (19.27%) | 518 (8.09%) | 73 (4.05%) | |
| Radiation | |||||||
| Yes | 197 (0.26%) | 125 (0.68%) | 20 (0.92%) | 62 (0.76%) | 35 (0.55%) | 8 (0.44%) | |
| No | 74,536 (99.74%) | 18,351 (99.32%) | 2,144 (99.08%) | 8,044 (99.24%) | 6367, (99.45%) | 1,796 (99.56%) | |
| Chemotherapy | |||||||
| Yes | 586 (0.78%) | 303 (1.64%) | 62 (2.87%) | 169 (2.08%) | 63 (0.98%) | 9 (0.50%) | |
| No | 74,147 (99.22%) | 18,173 (98.36%) | 2,102 (97.13%) | 7,937 (97.92%) | 6,339 (99.02%) | 1,795 (99.50%) | |
| Year of diagnosis | |||||||
| 2004–2007 | 20,681 (27.67%) | 8,079 (43.73%) | 688 (31.79%) | 2,528 (31.19%) | 3,129 (48.88%) | 1,734 (96.12%) | |
| 2008–2011 | 25,486 (34.10%) | 6,544 (35.42%) | 720 (33.27%) | 2,841 (35.05%) | 2,913 (45.50%) | 70 (3.88%) | |
| 2012–2015 | 28,566 (38.22%) | 3,853 (20.85%) | 756 (34.94%) | 2,737 (33.77%) | 360 (5.62%) | 0 (0.00%) | |
| Histology | |||||||
| Clear cell | 57,395 (76.80%) | 14,477 (78.36%) | 1,671 (77.22%) | 6,320 (77.97%) | 5,054 (78.94%) | 1,432 (79.38%) | |
| Papillary | 9,492 (12.70%) | 2,220 (12.02%) | 233 (10.77%) | 1,006 (12.41%) | 773 (12.07%) | 208 (11.53%) | |
| Chromophobe | 4,608 (6.17%) | 641 (3.47%) | 52 (2.40%) | 245 (3.02%) | 254 (3.97%) | 90 (4.99%) | |
| Other | 3,238 (4.33%) | 1,138 (6.16%) | 208 (9.61%) | 535 (6.60%) | 321 (5.01%) | 74 (4.10%) | |
| III | Sex | ||||||
| Male | 10,315 (68.50%) | 4,519 (68.35%) | 790 (64.54%) | 2,331 (69.01%) | 1,145 (69.48%) | 253 (69.89%) | |
| Female | 4,743 (31.50%) | 2,093 (31.65%) | 434 (35.46%) | 1,047 (30.99%) | 503 (30.52%) | 109 (30.11%) | |
| Age, years | |||||||
| <65 | 8,139 (54.05%) | 2,805 (42.42%) | 485 (39.62%) | 1,450 (42.92%) | 717 (43.51%) | 153 (42.27%) | |
| ≥65 | 6,919 (45.95%) | 3,807 (57.58%) | 739 (60.38%) | 1,928 (57.08%) | 931 (56.49%) | 209 (57.73%) | |
| Race | |||||||
| White | 12,919 (85.79%) | 5,641 (85.31%) | 981 (80.15%) | 2,890 (85.55%) | 1,442 (87.50%) | 328 (90.61%) | |
| Black | 1,180 (7.84%) | 591 (8.94%) | 164 (13.40%) | 289 (8.56%) | 121 (7.34%) | 17 (4.70%) | |
| Other | 959 (6.37%) | 380 (5.75%) | 79 (6.45%) | 199 (5.89%) | 85 (5.16%) | 17 (4.70%) | |
| Marital status | |||||||
| Married | 9,495 (63.06%) | 3,944 (59.65%) | 667 (54.49%) | 1,993 (59.00%) | 1,041 (63.17%) | 243 (67.13%) | |
| Never married | 2,099 (13.94%) | 904 (13.67%) | 172 (14.05%) | 481 (14.24%) | 207 (12.56%) | 44 (12.15%) | |
| Other | 3,464 (23.00%) | 1,764 (26.68%) | 385 (31.45%) | 904 (26.76%) | 400 (24.27%) | 75 (20.72%) | |
| Surgery | |||||||
| Yes | 14,567 (96.74%) | 6,190 (93.62%) | 1,008 (82.35%) | 3,209 (95.00%) | 1,615 (98.00%) | 358 (98.90%) | |
| No | 491 (3.26%) | 422 (6.38%) | 216 (17.65%) | 169 (5.00%) | 33 (2.00%) | 4 (1.10%) | |
| Radiation | |||||||
| Yes | 231 (1.53%) | 183 (2.77%) | 47 (3.84%) | 105 (3.11%) | 26 (1.58%) | 5 (1.38%) | |
| No | 14,827 (98.47%) | 6,429 (97.23%) | 1,177 (96.16%) | 3,273 (96.89%) | 1,622 (98.42%) | 357 (98.62%) | |
| Chemotherapy | |||||||
| Yes | 1,002 (6.65%) | 634 (9.59%) | 167 (13.64%) | 360 (10.66%) | 95 (5.76%) | 12 (3.31%) | |
| No | 14,056 (93.35%) | 5,978 (90.41%) | 1,057 (86.36%) | 3,018 (89.34%) | 1,553 (94.24%) | 350 (96.69%) | |
| Year of diagnosis | |||||||
| 2004–2007 | 4,310 (28.62%) | 2,697 (40.79%) | 414 (33.82%) | 1,110 (32.86%) | 830 (50.36%) | 343 (94.75%) | |
| 2008–2011 | 4,974 (33.03%) | 2,303 (34.83%) | 418 (34.15%) | 1,151 (34.07%) | 715 (43.39%) | 19 (5.25%) | |
| 2012–2015 | 5,774 (38.35%) | 1,612 (24.38%) | 392 (32.03%) | 1,117 (33.07%) | 103 (6.25%) | 0 (0.00%) | |
| Histology | |||||||
| Clear cell | 12,400 (82.35%) | 5,457 (82.53%) | 938 (76.63%) | 2,785 (82.45%) | 1,429 (86.71%) | 305 (84.25%) | |
| Papillary | 1,072 (7.12%) | 442 (6.68%) | 82 (6.70%) | 241 (7.13%) | 90 (5.46%) | 29 (8.01%) | |
| Chromophobe | 697 (4.63%) | 161 (2.43%) | 17 (1.39%) | 78 (2.31%) | 52 (3.16%) | 14 (3.87%) | |
| Other | 889 (5.90%) | 552 (8.35%) | 187 (15.28%) | 274 (8.11%) | 77 (4.67%) | 14 (3.87%) | |
| IV | Sex | ||||||
| Male | 11,064 (67.77%) | 9,822 (67.54%) | 5,721 (65.58%) | 3,598 (70.48%) | 437 (69.92%) | 66 (75.00%) | |
| Female | 5,263 (32.23%) | 4,720 (32.46%) | 3,003 (34.42%) | 1,507 (29.52%) | 188 (30.08%) | 22 (25.00%) | |
| Age, years | |||||||
| <65 | 8,846 (54.18%) | 7,679 (52.81%) | 4,351 (49.87%) | 2,893 (56.67%) | 380 (60.80%) | 55 (62.50%) | |
| ≥65 | 7,481 (45.82%) | 6,863 (47.19%) | 4,373 (50.13%) | 2,212 (43.33%) | 245 (39.20%) | 33 (37.50%) | |
| Race | |||||||
| White | 13,500 (82.69%) | 12,003 (82.54%) | 7,137 (81.81%) | 4,255 (83.35%) | 538 (86.08%) | 73 (82.95%) | |
| Black | 1,709 (10.47%) | 1,563 (10.75%) | 1,034 (11.85%) | 483 (9.46%) | 36 (5.76%) | 10 (11.36%) | |
| Other | 1,118 (6.85%) | 976 (6.71%) | 553 (6.34%) | 367 (7.19%) | 51 (8.16%) | 5 (5.68%) | |
| Marital status | |||||||
| Married | 9,495 (58.16%) | 8,374 (57.58%) | 4,845 (55.54%) | 3,074 (60.22%) | 396 (63.36%) | 59 (67.05%) | |
| Never married | 2,580 (15.80%) | 2,282 (15.69%) | 1,433 (16.43%) | 761 (14.91%) | 81 (12.96%) | 7 (7.95%) | |
| Other1 | 4,252 (26.04%) | 3,886 (26.72%) | 2,446 (28.04%) | 1,270 (24.88%) | 148 (23.68%) | 22 (25.00%) | |
| Surgery | |||||||
| Yes | 7,409 (45.38%) | 8,504 (58.48%) | 2,549 (29.22%) | 2,926 (57.32%) | 489 (78.24%) | 74 (84.09%) | |
| No | 8,918 (54.62%) | 6,038 (41.52%) | 6,175 (70.78%) | 2,179 (42.68%) | 136 (21.76%) | 14 (15.91%) | |
| Radiation | |||||||
| Yes | 4,529 (27.74%) | 4,273 (29.38%) | 2,678 (30.70%) | 1,471 (28.81%) | 112 (17.92%) | 12 (13.64%) | |
| No | 11,798 (72.26%) | 10,269 (70.62%) | 6,046 (69.30%) | 3,634 (71.19%) | 513 (82.08%) | 76 (86.36%) | |
| Chemotherapy | |||||||
| Yes | 8,572 (52.50%) | 7,039 (48.40%) | 3,935 (45.11%) | 2,857 (55.96%) | 221 (35.36%) | 26 (29.55%) | |
| No | 7,755 (47.50%) | 7,503 (51.60%) | 4,789 (54.89%) | 2,248 (44.04%) | 404 (64.64%) | 62 (70.45%) | |
| Year of diagnosis | |||||||
| 2004–2007 | 4,960 (30.38%) | 4,678 (32.17%) | 2,742 (31.43%) | 1,537 (30.11%) | 313 (50.08%) | 86 (97.73%) | |
| 2008–2011 | 5,383 (32.97%) | 4,940 (33.97%) | 2,916 (33.43%) | 1,753 (34.34%) | 269 (43.04%) | 2 (2.27%) | |
| 2012–2015 | 5,984 (36.65%) | 4,924 (33.86%) | 3,066 (35.14%) | 1,815 (35.55%) | 43 (6.88%) | 0 (0.00%) | |
| Histology | |||||||
| Clear cell | 13,337 (81.69%) | 11,875 (81.66%) | 6,988 (80.10%) | 4,297 (84.17%) | 522 (83.52%) | 68 (77.27%) | |
| Papillary | 698 (4.28%) | 612 (4.21%) | 304 (3.48%) | 264 (5.17%) | 37 (5.92%) | 7 (7.95%) | |
| Chromophobe | 145 (0.89%) | 112 (0.77%) | 46 (0.53%) | 47 (0.92%) | 14 (2.24%) | 5 (5.68%) | |
| Other | 2,147 (13.15%) | 1,943 (13.36%) | 1,386 (15.89%) | 497 (9.74%) | 52 (8.32%) | 8 (9.09%) | |
Other1 includes divorced, separated, widowed, and unmarried or domestic partner.
Causes of Death for Patients With Stage I/II RCC
Most deaths in patients with stage I or stage II disease occurred either within 1–5 years (n = 8,116 [43.93%]) or 5–10 years (n = 6,459 [34.96%]) (Table 1). In the stage I/II patient cohort, deaths from RCC accounted for 23.13% of all deaths (n = 4,273) and the proportion decreased gradually with the extension of survival time (Table 2). Noncancer causes of death (n = 11,235 [60.81%]) and non-RCC deaths (n = 2,853 [15.44%]) were 3.94-fold more frequent (60.81% vs. 15.44%; Table 2). Heart disease was the most common noncancer cause of death (n = 3,718 [20.12% of all-cause deaths]), and the proportion increased with the extension of survival time (Figure 2A). The most common causes of non-RCC cancer deaths were respiratory system and digestive system cancers (n = 803 [4.35%] for respiratory system cancer and n = 815 [4.41%] for digestive system cancer). Over the whole follow-up period, the risk of death was greater than that in the general population (SMR, 1.54; 95% CI, 1.52–1.56), with the highest risk observed within the first year after RCC diagnosis (SMR, 1.81; 95% CI, 1.74–1.89), the risk levels gradually became stable (SMR, 1.51 for 1 to <5 years; SMR, 1.52 for 5 to <10 years; SMR, 1.51 for ≥10 years). The risk of almost all deaths increased except for breast tumors (SMR, 0.38; 95% CI, 0.28–0.5) and Alzheimer’s disease (SMR, 0.84; 95% CI, 0.75–0.93) (Table 1). Ten or more years after the diagnosis of RCC, RCC-specific mortality was still elevated (SMR, 46.01; 95% CI, 40.95–51.52).
Table 2.
Causes of death for patients with stage I/II RCC.
| Timing of Death After Diagnosis | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All Years | <1 year | 1 to <5 years | 5 to <10 years | ≥10 years | ||||||
| Cause of Death | No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) |
| All causes of death | 18,476 (100.00%) | 1.54# (1.52–1.56) | 2,069 (100.00%) | 1.81# (1.74–1.89) | 8,116 (100.00%) | 1.51# (1.48–1.54) | 6,459 (100.00%) | 1.52# (1.48–1.56) | 1,832 (100.00%) | 1.51# (1.44–1.58) |
| All malignant cancers | 7,126 (38.57%) | 2.45# (2.4–2.51) | 844 (40.79%) | 2.83# (2.64–3.03) | 3,416 (42.09%) | 2.53# (2.45–2.62) | 2,234 (34.59%) | 2.25# (2.16–2.34) | 632 (34.50%) | 2.39# (2.21–2.58) |
| Oral cavity/pharynx/eye/endocrine | 51 (0.28%) | 0.84 (0.62–1.1) | 5 (0.24%) | 0.81 (0.26–1.9) | 25 (0.31%) | 0.89 (0.57–1.31) | 15 (0.23%) | 0.72 (0.4–1.18) | 6 (0.33%) | 1.07 (0.39–2.32) |
| Digestive system | 815 (4.41%) | 1.08# (1.01–1.16) | 80 (3.87%) | 1.04 (0.83–1.3) | 327 (4.03%) | 0.93 (0.84–1.04) | 304 (4.71%) | 1.17# (1.04–1.31) | 104 (5.68%) | 1.50# (1.23–1.82) |
| Respiratory system | 803 (4.35%) | 0.97 (0.9–1.04) | 51 (2.46%) | 0.57# (0.42–0.74) | 361 (4.45%) | 0.92 (0.82–1.02) | 307 (4.75%) | 1.11 (0.99–1.24) | 84 (4.59%) | 1.2 (0.96–1.49) |
| Bones and joints/soft tissue/skin | 70 (0.38%) | 0.81 (0.63–1.02) | 9 (0.43%) | 1.04 (0.48–1.98) | 26 (0.32%) | 0.65# (0.43–0.96) | 25 (0.39%) | 0.83 (0.54–1.23) | 10 (0.55%) | 1.23 (0.59–2.26) |
| Breast | 51 (0.28%) | 0.38# (0.28–0.5) | 2 (0.10%) | 0.14# (0.02–0.51) | 13 (0.16%) | 0.21# (0.11–0.35) | 25 (0.39%) | 0.55# (0.36–0.82) | 11 (0.60%) | 0.93 (0.47–1.67) |
| Genital system | 183 (0.99%) | 0.61# (0.53–0.71) | 16 (0.77%) | 0.55# (0.32–0.9) | 81 (1.00%) | 0.60# (0.48–0.74) | 58 (0.90%) | 0.55# (0.42–0.71) | 28 (1.53%) | 0.94 (0.63–1.36) |
| Kidney and renal pelvis | 4,273 (23.13%) | 59.77# (57.99–61.59) | 584 (28.23%) | 79.88# (73.53–86.63) | 2,189 (26.97%) | 66.01# (63.27–68.83) | 1,200 (18.58%) | 49.00# (46.26–51.85) | 300 (16.38%) | 46.01# (40.95–51.52) |
| Other urinary organs | 98 (0.53%) | 1.04 (0.85–1.27) | 7 (0.34%) | 0.81 (0.33–1.67) | 56 (0.69%) | 1.34# (1.01–1.74) | 29 (0.45%) | 0.86 (0.57–1.23) | 6 (0.33%) | 0.61 (0.22–1.33) |
| Brain/other nervous system | 98 (0.53%) | 1.48# (1.2–1.81) | 7 (0.34%) | 1.03 (0.41–2.11) | 46 (0.57%) | 1.49# (1.09–1.99) | 36 (0.56%) | 1.61# (1.12–2.22) | 9 (0.49%) | 1.52 (0.7–2.89) |
| Lymph/blood | 315 (1.70%) | 1.1 (0.98–1.23) | 45 (2.17%) | 1.58# (1.15–2.11) | 129 (1.59%) | 0.99 (0.82–1.17) | 110 (1.70%) | 1.1 (0.91–1.33) | 31 (1.69%) | 1.14 (0.78–1.62) |
| Miscellaneous malignant cancer | 369 (2.00%) | 1.69# (1.52–1.87) | 38 (1.84%) | 1.71# (1.21–2.35) | 163 (2.01%) | 1.62# (1.38–1.89) | 125 (1.94%) | 1.66# (1.38–1.98) | 43 (2.35%) | 2.10# (1.52–2.83) |
| In situ, benign or unknown behavior neoplasm | 115 (0.62%) | 1.51# (1.25–1.81) | 14 (0.68%) | 1.98# (1.08–3.33) | 51 (0.63%) | 1.51# (1.12–1.98) | 43 (0.67%) | 1.57# (1.13–2.11) | 7 (0.38%) | 0.89 (0.36–1.83) |
| Noncancer | 11,235 (60.81%) | 1.25# (1.22–1.27) | 1,211 (58.53%) | 1.45# (1.37–1.53) | 4,649 (57.28%) | 1.16# (1.13–1.2) | 4,182 (64.75%) | 1.29# (1.25–1.33) | 1,193 (65.12%) | 1.27# (1.2–1.34) |
| Infections | 446 (2.41%) | 1.50# (1.36–1.64) | 59 (2.85%) | 1.96# (1.49–2.53) | 193 (2.38%) | 1.41# (1.22–1.62) | 155 (2.40%) | 1.51# (1.28–1.77) | 39 (2.13%) | 1.4 (1–1.91) |
| Diabetes mellitus | 721 (3.90%) | 1.91# (1.77–2.05) | 92 (4.45%) | 2.45# (1.98–3.01) | 309 (3.81%) | 1.78# (1.59–1.99) | 257 (3.98%) | 1.95# (1.72–2.21) | 63 (3.44%) | 1.74# (1.34–2.22) |
| Alzheimer’s (ICD-9 and 10 only) | 363 (1.96%) | 0.84# (0.75–0.93) | 20 (0.97%) | 0.64# (0.39–0.98) | 114 (1.40%) | 0.66# (0.54–0.79) | 170 (2.63%) | 1 (0.86–1.17) | 59 (3.22%) | 1.01 (0.77–1.3) |
| Diseases of heart | 3,718 (20.12%) | 1.23# (1.19–1.27) | 411 (19.86%) | 1.42# (1.29–1.56) | 1,567 (19.31%) | 1.16# (1.1–1.22) | 1,350 (20.90%) | 1.26# (1.19–1.33) | 390 (21.29%) | 1.26# (1.14–1.39) |
| Hypertension without heart disease | 320 (1.73%) | 2.25# (2.01–2.52) | 30 (1.45%) | 2.46# (1.66–3.51) | 121 (1.49%) | 1.97# (1.64–2.36) | 126 (1.95%) | 2.40# (2–2.86) | 43 (2.35%) | 2.70# (1.96–3.64) |
| Cerebrovascular diseases | 710 (3.84%) | 1.11# (1.03–1.19) | 75 (3.62%) | 1.26 (0.99–1.58) | 317 (3.91%) | 1.12# (1–1.25) | 237 (3.67%) | 1.03 (0.9–1.17) | 81 (4.42%) | 1.18 (0.94–1.47) |
| Diseases of arteries | 154 (0.83%) | 1.21# (1.02–1.41) | 25 (1.21%) | 1.91# (1.23–2.82) | 57 (0.70%) | 0.97 (0.74–1.26) | 59 (0.91%) | 1.35# (1.03–1.74) | 13 (0.71%) | 1.08 (0.57–1.84) |
| Pneumonia and influenza | 1,022 (5.53%) | 1.01 (0.95–1.08) | 94 (4.54%) | 1 (0.81–1.22) | 414 (5.10%) | 0.92 (0.83–1.01) | 419 (6.49%) | 1.16# (1.05–1.28) | 95 (5.19%) | 0.92 (0.74–1.12) |
| Digestive | 231 (1.25%) | 1.41# (1.23–1.6) | 31 (1.50%) | 1.78# (1.21–2.53) | 110 (1.36%) | 1.42# (1.16–1.71) | 76 (1.18%) | 1.39# (1.1–1.74) | 14 (0.76%) | 1 (0.55–1.68) |
| Nephritis/nephrotic syndrome/nephrosis | 716 (3.88%) | 2.95# (2.74–3.18) | 78 (3.77%) | 3.43# (2.71–4.29) | 287 (3.54%) | 2.65# (2.35–2.97) | 266 (4.12%) | 3.07# (2.71–3.46) | 85 (4.64%) | 3.42# (2.73–4.23) |
| Pregnancy/childbirth/puerperium | 28 (0.15%) | 2.27# (1.51–3.28) | 1 (0.05%) | 0.74 (0.02–4.15) | 11 (0.14%) | 1.87 (0.93–3.34) | 12 (0.19%) | 2.94# (1.52–5.14) | 4 (0.22%) | 3.83# (1.04–9.8) |
| Symptoms, signs, and ill-defined conditions | 150 (0.81%) | 1.16 (0.98–1.36) | 15 (0.72%) | 1.23 (0.69–2.04) | 65 (0.80%) | 1.12 (0.86–1.43) | 60 (0.93%) | 1.29 (0.98–1.65) | 10 (0.55%) | 0.82 (0.39–1.5) |
| Accidents/adverse effects/homicide/legal intervention | 468 (2.53%) | 1.13# (1.03–1.24) | 50 (2.42%) | 1.21 (0.9–1.59) | 210 (2.59%) | 1.1 (0.96–1.26) | 159 (2.46%) | 1.11 (0.95–1.3) | 49 (2.67%) | 1.24 (0.91–1.63) |
| Suicide/self-inflicted injury | 105 (0.57%) | 1.01 (0.82–1.22) | 8 (0.39%) | 0.68 (0.3–1.35) | 50 (0.62%) | 0.99 (0.73–1.3) | 38 (0.59%) | 1.12 (0.8–1.54) | 9 (0.49%) | 1.08 (0.5–2.06) |
| Other cause of death | 2,083 (11.27%) | 1.10# (1.06–1.15) | 222 (10.73%) | 1.38# (1.2–1.57) | 824 (10.15%) | 1.01 (0.95–1.09) | 798 (12.35%) | 1.14# (1.06–1.22) | 239 (13.05%) | 1.14 (1–1.29) |
#p < 0.05; SMRs, standardized mortality ratios; CI, confidence interval.
Figure 2.
Causes of death by stage after the diagnosis of RCC; (A) stage I/II, (B)stage III,(C) stage RCC.
Causes of Death for Patients With Stage III RCC
Of the 15,058 patients with stage III RCC, 6,612 (43.91%) died within the follow-up period, 4,574 (30.38%) of whom died from malignant tumors, 3,912 (25.98%) died from RCC, and 2,014 (13.37%) died from noncancer causes. Heart disease was the most common noncancer cause of death (n = 708 [10.71% of all deaths]), and miscellaneous malignant cancer was the most common cause of other cancer deaths (n = 162 [2.45%]) (Figure 2B). Over the entire follow-up period, the mortality rate was greater than that of the general population (SMR, 2.93; 95% CI, 2.86–3.00). The SMR was the highest in the first year of diagnosis (SMR, 4.54; 95% CI, 4.29–4.81), and the risk levels gradually declined (SMR, 3.15, 1 to <5 years; SMR, 2.30 for 5 to <10 years; SMR, 1.88 for ≥10 years).
Causes of Death for Patients With Stage IV RCC
Most patients (94.99%) with stage IV RCC died within 5 years of the initial diagnosis (8,499 [58.44%] within the first year and 5,315 [36.55%] between 1 and 5 years; Table 1). RCC was the leading cause of death (n = 12,310 [84.65%]), with other cancers (n = 1,122 [7.72%]) and noncancer causes (n = 1,110 [7.63%]) accounting for only a small proportion (Table 4). Men with stage IV RCC were at a higher risk than the general population (SMR, 21.84; 95% CI, 21.49–22.20). The risk of death from RCC was substantial over all follow-up years (SMR, 2,889.25; 95% CI, 2,838.43–2,940.75) (Figure 2C). Heart disease was the most common noncancer cause of death (n = 328 [2.23%]). In contrast to other stages, stage IV patients also had a higher risk of suicide (SMR, 3.46; 95% CI, (2.17–5.24).
Table 4.
Causes of death for patients with stage IV RCC.
| Timing of Death After Diagnosis | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All Years | <1 year | 1 to <5 years | 5 to <10 years | ≥10 years | ||||||
| Cause of Death | No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) |
| All causes of death | 14,542 (100.00%) | 21.84# (21.49–22.2) | 8,499 (100.00%) | 45.20# (44.24–46.17) | 5,315 (100.00%) | 16.25# (15.82–16.69) | 639 (100.00%) | 5.23# (4.84–5.66) | 89 (100.00%) | 3.11# (2.5–3.83) |
| All malignant cancers | 13,396 (92.12%) | 80.42# (79.07–81.8) | 7,988 (93.99%) | 165.57# (161.95–169.24) | 4,841 (91.08%) | 58.04# (56.42–59.7) | 514 (80.44%) | 17.91# (16.39–19.52) | 53 (59.55%) | 8.54# (6.4–11.17) |
| Oral cavity/pharynx/eye/endocrine | 12 (0.08%) | 3.34# (1.73–5.84) | 9 (0.11%) | 8.92# (4.08–16.93) | 2 (0.04%) | 1.1 (0.13–3.97) | 0 (0.00%) | 0 (0–5.91) | 1 (1.12%) | 7.41 (0.19–41.29) |
| Digestive system | 105 (0.72%) | 2.40# (1.97–2.91) | 59 (0.69%) | 4.73# (3.6–6.1) | 38 (0.71%) | 1.73# (1.22–2.37) | 6 (0.94%) | 0.79 (0.29–1.72) | 2 (2.25%) | 1.23 (0.15–4.46) |
| Respiratory system | 226 (1.55%) | 4.60# (4.02–5.24) | 142 (1.67%) | 9.71# (8.18–11.44) | 71 (1.34%) | 2.87# (2.24–3.62) | 10 (1.56%) | 1.24 (0.59–2.27) | 3 (3.37%) | 1.83 (0.38–5.34) |
| Bones and joints/soft tissue/skin | 39 (0.27%) | 7.64# (5.43–10.45) | 25 (0.29%) | 17.40# (11.26–25.69) | 11 (0.21%) | 4.30# (2.15–7.7) | 3 (0.47%) | 3.32 (0.68–9.71) | 0 (0.00%) | 0 (0–17.97) |
| Breast | 7 (0.05%) | 1.17 (0.47–2.42) | 3 (0.04%) | 1.64 (0.34–4.8) | 3 (0.06%) | 1.03 (0.21–3) | 0 (0.00%) | 0 (0–3.62) | 1 (1.12%) | 5 (0.13–27.83) |
| Genital system | 42 (0.29%) | 2.54# (1.83–3.44) | 25 (0.29%) | 5.30# (3.43–7.83) | 15 (0.28%) | 1.85# (1.03–3.05) | 2 (0.31%) | 0.67 (0.08–2.43) | 0 (0.00%) | 0 (0–5.25) |
| Kidney and renal pelvis | 12,310 (84.65%) | 2,889.25# (2,838.43–2,940.75) | 7,308 (85.99%) | 6,003.28# (5,866.42–6,142.52) | 4,498 (84.63%) | 2,095.36# (2,034.57–2,157.51) | 463 (72.46%) | 628.07# (572.16–687.97) | 41 (46.07%) | 257.12# (184.51–348.81) |
| Other urinary organs | 88 (0.61%) | 16.05# (12.87–19.77) | 59 (0.69%) | 39.25# (29.88–50.64) | 28 (0.53%) | 10.39# (6.9–15.01) | 1 (0.16%) | 0.97 (0.02–5.43) | 0 (0.00%) | 0 (0–14.31) |
| Brain/other nervous system | 21 (0.14%) | 5.45# (3.37–8.33) | 11 (0.13%) | 10.09# (5.03–18.05) | 7 (0.13%) | 3.56# (1.43–7.35) | 3 (0.47%) | 4.54 (0.94–13.28) | 0 (0.00%) | 0 (0–26.47) |
| Lymph/blood | 73 (0.50%) | 4.45# (3.48–5.59) | 34 (0.40%) | 7.23# (5–10.1) | 29 (0.55%) | 3.55# (2.38–5.1) | 7 (1.10%) | 2.42 (0.97–4.98) | 3 (3.37%) | 4.56 (0.94–13.34) |
| Miscellaneous malignant cancer | 473 (3.25%) | 37.57# (34.26–41.11) | 313 (3.68%) | 86.16# (76.88–96.25) | 139 (2.62%) | 22.13# (18.61–26.13) | 19 (2.97%) | 8.68# (5.22–13.55) | 2 (2.25%) | 4.11 (0.5–14.85) |
| In situ, benign, or unknown behavior neoplasm | 36 (0.25%) | 8.44# (5.91–11.68) | 21 (0.25%) | 17.67# (10.94–27) | 14 (0.26%) | 6.71# (3.67–11.25) | 0 (0.00%) | 0 (0–4.63) | 1 (1.12%) | 5.18 (0.13–28.88) |
| Noncancer | 1,110 (7.63%) | 2.24# (2.11–2.38) | 490 (5.77%) | 3.54# (3.23–3.86) | 460 (8.65%) | 1.90# (1.73–2.09) | 125 (19.56%) | 1.35# (1.12–1.61) | 35 (39.33%) | 1.58# (1.1–2.19) |
| Infections | 65 (0.45%) | 3.95# (3.05–5.04) | 33 (0.39%) | 6.93# (4.77–9.74) | 25 (0.47%) | 3.06# (1.98–4.52) | 6 (0.94%) | 2.08 (0.76–4.52) | 1 (1.12%) | 1.58 (0.04–8.83) |
| Diabetes mellitus | 57 (0.39%) | 2.69# (2.04–3.48) | 21 (0.25%) | 3.49# (2.16–5.33) | 22 (0.41%) | 2.08# (1.31–3.16) | 9 (1.41%) | 2.38# (1.09–4.52) | 5 (5.62%) | 5.95# (1.93–13.88) |
| Alzheimer’s (ICD-9 and 10 only) | 21 (0.14%) | 0.98 (0.61–1.5) | 5 (0.06%) | 0.92 (0.3–2.14) | 12 (0.23%) | 1.21 (0.63–2.12) | 2 (0.31%) | 0.43 (0.05–1.55) | 2 (2.25%) | 1.48 (0.18–5.34) |
| Diseases of heart | 328 (2.26%) | 1.92# (1.72–2.14) | 157 (1.85%) | 3.22# (2.74–3.76) | 125 (2.35%) | 1.50# (1.25–1.79) | 35 (5.48%) | 1.12 (0.78–1.56) | 11 (12.36%) | 1.48 (0.74–2.65) |
| Hypertension without heart disease | 22 (0.15%) | 2.96# (1.86–4.48) | 8 (0.09%) | 4.02# (1.74–7.92) | 13 (0.24%) | 3.63# (1.93–6.2) | 1 (0.16%) | 0.67 (0.02–3.73) | 0 (0.00%) | 0 (0–10.12) |
| Cerebrovascular diseases | 87 (0.60%) | 2.51# (2.01–3.09) | 31 (0.36%) | 3.13# (2.13–4.45) | 40 (0.75%) | 2.39# (1.71–3.25) | 14 (2.19%) | 2.16# (1.18–3.62) | 2 (2.25%) | 1.26 (0.15–4.56) |
| Diseases of arteries | 18 (0.12%) | 2.43# (1.44–3.84) | 7 (0.08%) | 3.15# (1.27–6.5) | 9 (0.17%) | 2.48# (1.14–4.71) | 2 (0.31%) | 1.56 (0.19–5.64) | 0 (0.00%) | 0 (0–12.91) |
| Pneumonia and influenza | 123 (0.85%) | 2.20# (1.83–2.62) | 51 (0.60%) | 3.24# (2.41–4.26) | 55 (1.03%) | 2.01# (1.51–2.61) | 15 (2.35%) | 1.45 (0.81–2.4) | 2 (2.25%) | 0.81 (0.1–2.94) |
| Digestive | 15 (0.10%) | 1.55 (0.87–2.55) | 4 (0.05%) | 1.45 (0.39–3.7) | 11 (0.21%) | 2.20# (1.1–3.93) | 0 (0.00%) | 0 (0–2.28) | 0 (0.00%) | 0 (0–11.65) |
| Nephritis/nephrotic syndrome/nephrosis | 49 (0.34%) | 3.70# (2.74–4.89) | 22 (0.26%) | 5.90# (3.7–8.93) | 18 (0.34%) | 2.79# (1.65–4.41) | 7 (1.10%) | 2.83# (1.14–5.83) | 2 (2.25%) | 3.44 (0.42–12.43) |
| Pregnancy/childbirth/puerperium | 8 (0.06%) | 11.54# (4.98–22.74) | 3 (0.04%) | 14.90# (3.07–43.54) | 5 (0.09%) | 14.11# (4.58–32.93) | 0 (0.00%) | 0 (0–32.33) | 0 (0.00%) | 0 (0–158.67) |
| Symptoms, signs, and ill-defined conditions | 33 (0.23%) | 4.65# (3.2–6.53) | 19 (0.22%) | 9.43# (5.68–14.73) | 13 (0.24%) | 3.79# (2.02–6.48) | 1 (0.16%) | 0.73 (0.02–4.09) | 0 (0.00%) | 0 (0–13.05) |
| Accidents/adverse effects/homicide/legal intervention | 50 (0.34%) | 2.20# (1.63–2.9) | 16 (0.19%) | 2.49# (1.42–4.04) | 27 (0.51%) | 2.36# (1.56–3.44) | 4 (0.63%) | 1 (0.27–2.57) | 3 (3.37%) | 3.24 (0.67–9.48) |
| Suicide/self-inflicted injury | 22 (0.15%) | 3.46# (2.17–5.24) | 12 (0.14%) | 6.55# (3.39–11.45) | 9 (0.17%) | 2.73# (1.25–5.18) | 1 (0.16%) | 0.97 (0.02–5.43) | 0 (0.00%) | 0 (0–18.28) |
| Other cause of death | 212 (1.46%) | 2.12# (1.84–2.43) | 101 (1.19%) | 3.77# (3.07–4.58) | 76 (1.43%) | 1.57# (1.24–1.97) | 28 (4.38%) | 1.4 (0.93–2.03) | 7 (7.87%) | 1.42 (0.57–2.92) |
#p < 0.05; SMRs, standardized mortality ratios; CI, confidence interval.
Table 3.
Causes of death for patients with stage III RCC.
| Timing of Death After Diagnosis | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All Years | <1 year | 1 to <5 years | 5 to <10 years | ≥10 years | ||||||
| Cause of Death | No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) |
| All causes of death | 6,612 (100.00%) | 2.93# (2.86–3) | 1,174 (100.00%) | 4.54# (4.29–4.81) | 3,400 (100.00%) | 3.15# (3.05–3.26) | 1,672 (100.00%) | 2.30# (2.19–2.41) | 366 (100.00%) | 1.88# (1.69–2.08) |
| All malignant cancers | 4,574 (69.18%) | 8.31# (8.07–8.55) | 888 (75.64%) | 13.07# (12.23–13.96) | 2,530 (74.41%) | 9.33# (8.97–9.7) | 968 (57.89%) | 5.70# (5.35–6.07) | 188 (51.37%) | 4.52# (3.89–5.21) |
| Oral cavity/pharynx/eye/endocrine | 8 (0.12%) | 0.69 (0.3–1.36) | 2 (0.17%) | 1.42 (0.17–5.13) | 0 (0.00%) | 0.00# (0–0.65) | 4 (0.24%) | 1.12 (0.3–2.86) | 2 (0.55%) | 2.25 (0.27–8.13) |
| Digestive system | 142 (2.15%) | 1 (0.84–1.18) | 18 (1.53%) | 1.03 (0.61–1.63) | 69 (2.03%) | 0.98 (0.77–1.25) | 46 (2.75%) | 1.05 (0.77–1.39) | 9 (2.46%) | 0.83 (0.38–1.58) |
| Respiratory system | 176 (2.66%) | 1.1 (0.94–1.28) | 11 (0.94%) | 0.53# (0.26–0.94) | 88 (2.59%) | 1.1 (0.88–1.35) | 60 (3.59%) | 1.26 (0.96–1.62) | 17 (4.64%) | 1.54 (0.9–2.47) |
| Bones and joints/soft tissue/skin | 17 (0.26%) | 0.99 (0.57–1.58) | 3 (0.26%) | 1.46 (0.3–4.26) | 9 (0.26%) | 1.07 (0.49–2.03) | 4 (0.24%) | 0.74 (0.2–1.89) | 1 (0.27%) | 0.74 (0.02–4.1) |
| Breast | 13 (0.20%) | 0.65 (0.35–1.12) | 1 (0.09%) | 0.39 (0.01–2.2) | 2 (0.06%) | 0.20# (0.02–0.74) | 7 (0.42%) | 1.16 (0.47–2.4) | 3 (0.82%) | 2.02 (0.42–5.91) |
| Genital system | 26 (0.39%) | 0.47# (0.3–0.68) | 1 (0.09%) | 0.15# (0–0.86) | 10 (0.29%) | 0.37# (0.18–0.69) | 14 (0.84%) | 0.78 (0.43–1.32) | 1 (0.27%) | 0.21 (0.01–1.2) |
| Kidney and renal pelvis | 3,912 (59.17%) | 279.28# (270.6–288.17) | 806 (68.65%) | 468.31# (436.54–501.79) | 2,211 (65.03%) | 320.15# (306.94–333.78) | 758 (45.33%) | 175.32# (163.06–188.26) | 137 (37.43%) | 129.65# (108.85–153.27) |
| Other urinary organs | 44 (0.67%) | 2.28# (1.65–3.05) | 2 (0.17%) | 0.93 (0.11–3.37) | 28 (0.82%) | 3.06# (2.03–4.42) | 13 (0.78%) | 2.05# (1.09–3.5) | 1 (0.27%) | 0.59 (0.01–3.27) |
| Brain/other nervous system | 22 (0.33%) | 1.76# (1.1–2.66) | 0 (0.00%) | 0 (0–2.37) | 14 (0.41%) | 2.24# (1.23–3.76) | 7 (0.42%) | 1.83 (0.74–3.78) | 1 (0.27%) | 1.09 (0.03–6.08) |
| Lymph/blood | 52 (0.79%) | 0.93 (0.69–1.22) | 8 (0.68%) | 1.2 (0.52–2.36) | 27 (0.79%) | 0.99 (0.66–1.45) | 13 (0.78%) | 0.74 (0.39–1.26) | 4 (1.09%) | 0.9 (0.24–2.3) |
| Miscellaneous malignant cancer | 162 (2.45%) | 3.86# (3.29–4.51) | 36 (3.07%) | 7.05# (4.94–9.76) | 72 (2.12%) | 3.51# (2.75–4.42) | 42 (2.51%) | 3.22# (2.32–4.36) | 12 (3.28%) | 3.66# (1.89–6.4) |
| In situ, benign or unknown behavior neoplasm | 24 (0.36%) | 1.60# (1.03–2.38) | 3 (0.26%) | 1.8 (0.37–5.26) | 9 (0.26%) | 1.27 (0.58–2.41) | 9 (0.54%) | 1.83 (0.84–3.48) | 3 (0.82%) | 2.28 (0.47–6.66) |
| Noncancer | 2,014 (30.46%) | 1.19# (1.14–1.24) | 283 (24.11%) | 1.50# (1.33–1.68) | 861 (25.32%) | 1.08# (1.01–1.15) | 695 (41.57%) | 1.26# (1.17–1.35) | 175 (47.81%) | 1.15 (0.99–1.33) |
| Infections | 95 (1.44%) | 1.78# (1.44–2.17) | 25 (2.13%) | 3.89# (2.52–5.74) | 32 (0.94%) | 1.23 (0.84–1.73) | 28 (1.67%) | 1.67# (1.11–2.41) | 10 (2.73%) | 2.34# (1.12–4.31) |
| Diabetes mellitus | 130 (1.97%) | 1.87# (1.57–2.22) | 13 (1.11%) | 1.57 (0.84–2.69) | 61 (1.79%) | 1.81# (1.38–2.32) | 43 (2.57%) | 1.97# (1.42–2.65) | 13 (3.55%) | 2.33# (1.24–3.99) |
| Alzheimer’s (ICD-9 and 10 only) | 61 (0.92%) | 0.75# (0.58–0.97) | 3 (0.26%) | 0.42 (0.09–1.23) | 26 (0.76%) | 0.74 (0.49–1.09) | 25 (1.50%) | 0.86 (0.56–1.27) | 7 (1.91%) | 0.72 (0.29–1.48) |
| Diseases of heart | 708 (10.71%) | 1.23# (1.14–1.32) | 109 (9.28%) | 1.64# (1.35–1.98) | 298 (8.76%) | 1.09 (0.97–1.22) | 249 (14.89%) | 1.34# (1.18–1.52) | 52 (14.21%) | 1.03 (0.77–1.35) |
| Hypertension without heart disease | 41 (0.62%) | 1.63# (1.17–2.2) | 4 (0.34%) | 1.54 (0.42–3.93) | 13 (0.38%) | 1.12 (0.6–1.92) | 20 (1.20%) | 2.34# (1.43–3.61) | 4 (1.09%) | 1.63 (0.44–4.16) |
| Cerebrovascular diseases | 146 (2.21%) | 1.23# (1.04–1.44) | 20 (1.70%) | 1.5 (0.92–2.32) | 65 (1.91%) | 1.16 (0.9–1.48) | 50 (2.99%) | 1.29 (0.95–1.69) | 11 (3.01%) | 1 (0.5–1.79) |
| Diseases of arteries | 22 (0.33%) | 0.89 (0.56–1.35) | 1 (0.09%) | 0.33 (0.01–1.83) | 12 (0.35%) | 1 (0.52–1.75) | 7 (0.42%) | 0.92 (0.37–1.9) | 2 (0.55%) | 1.02 (0.12–3.69) |
| Pneumonia and influenza | 191 (2.89%) | 0.97 (0.84–1.12) | 19 (1.62%) | 0.86 (0.52–1.34) | 81 (2.38%) | 0.87 (0.69–1.08) | 73 (4.37%) | 1.15 (0.9–1.44) | 18 (4.92%) | 1.06 (0.63–1.67) |
| Digestive | 48 (0.73%) | 1.60# (1.18–2.13) | 5 (0.43%) | 1.3 (0.42–3.04) | 21 (0.62%) | 1.39 (0.86–2.12) | 17 (1.02%) | 1.92# (1.12–3.07) | 5 (1.37%) | 2.43 (0.79–5.67) |
| Nephritis/nephrotic syndrome/nephrosis | 94 (1.42%) | 2.10# (1.69–2.57) | 6 (0.51%) | 1.19 (0.44–2.6) | 43 (1.26%) | 2.02# (1.46–2.72) | 33 (1.97%) | 2.26# (1.55–3.17) | 12 (3.28%) | 3.07# (1.59–5.36) |
| Pregnancy/childbirth/puerperium | 6 (0.09%) | 2.84# (1.04–6.17) | 2 (0.17%) | 7.26 (0.88–26.23) | 3 (0.09%) | 2.8 (0.58–8.19) | 1 (0.06%) | 1.61 (0.04–8.95) | 0 (0.00%) | 0 (0–25.11) |
| Symptoms, signs, and ill-defined conditions | 35 (0.53%) | 1.47# (1.03–2.05) | 8 (0.68%) | 3.01# (1.3–5.92) | 19 (0.56%) | 1.68# (1.01–2.63) | 8 (0.48%) | 1.02 (0.44–2.01) | 0 (0.00%) | 0 (0–1.87) |
| Accidents/adverse effects/homicide/legal intervention | 64 (0.97%) | 0.86 (0.66–1.1) | 8 (0.68%) | 0.91 (0.39–1.8) | 34 (1.00%) | 0.94 (0.65–1.32) | 20 (1.20%) | 0.86 (0.53–1.33) | 2 (0.55%) | 0.33 (0.04–1.18) |
| Suicide/self-inflicted injury | 13 (0.20%) | 0.67 (0.36–1.15) | 1 (0.09%) | 0.39 (0.01–2.17) | 10 (0.29%) | 1.01 (0.48–1.86) | 2 (0.12%) | 0.36 (0.04–1.29) | 0 (0.00%) | 0 (0–2.93) |
| Other cause of death | 360 (5.44%) | 1.02 (0.91–1.13) | 59 (5.03%) | 1.62# (1.23–2.09) | 143 (4.21%) | 0.88 (0.74–1.03) | 119 (7.12%) | 0.99 (0.82–1.18) | 39 (10.66%) | 1.14 (0.81–1.56) |
#p < 0.05; SMRs, standardized mortality ratios; CI, confidence interval.
Subgroup Analysis
Male and female patients had a similar risk of all-cause death, but female patients (SMR, 330.10; 95% CI, 322.25–338.08) had a higher risk of intentional deaths from RCC than male patients (SMR, 198.48; 95% CI, 195.18–201.83) (Tables S1 and S2). Compared with patients aged <65 years, the risk of death of patients aged ≥65 years was higher than that of patients aged <65 years (Tables S3 and S4). Patients of other races have a higher risk of all-cause death than black and white patients (SMR, 4.29; 95% CI, 4.12–4.47 for other races; SMR, 2.57; 95% CI, 2.54–2.59 for white; SMR, 2.85; 95% CI, 2.77–2.93 for black) (Tables S5–S7). Patients who have never been married have a higher risk of death than those who are married and in other marital statuses, regardless of whether it is a cancer or a noncancer factor (Tables S8–S10). Noncancer causes of death were lower in patients who underwent surgery than in those who did not (Tables S11 and S12). In contrast, patients who received chemotherapy or radiotherapy showed an increase in noncancer causes of death (Tables S13–S16). There was no significant difference in SMR between the different years of diagnosis (Tables S17–S19). The prognosis of patients with other histological types was the worst, and the prognosis of patients with chromophobe histological type was the best (SMR, 1.08; 95% CI, 1.01–1.16 for chromophobe histological type; SMR,4.37; 95% CI, 4.23–4.51 for other histological types) (Tables S20–S23).
Discussion
In the U.S., there are more than 320,000 RCC survivors, and the number is still increasing. It is of vital importance, during survivorship, to optimize healthcare management. We stratified our results according to patient characteristics and stage. In the patient cohort with stage I/II RCC, non-RCC causes of death were 3.32-fold more frequent (76.87% vs. 23.13%, respectively). In patients with stage III/IV disease, 59.17% (n = 3,912) and 84.65% (n = 12,310) of the patients died from RCC, respectively, and the risk of death due to most non-RCC causes was still higher than that in the general population. These results mirror those of previous studies (11).
Our study demonstrates the causes of death in RCC patients with different stages and characteristics, which may help clinicians. For example, the prevention and control of noncancer causes and screening for non-kidney cancer can be emphasized.
In patients with RCC, the most common noncancer death was heart disease. In our study, patients with stage IV disease had a higher SMR in heart disease than those with stage I/II and III (SMR, 1.92; 95% CI, 1.72–2.14 for stage IV; SMR, 1.23; 95% CI, 1.14–1.32 for stage III; SMR, 1.23; 95% CI, 1.19–1.27 for stage I/II). In the past decade, several tyrosine kinases and vascular endothelial growth factor inhibitors have been used for first-line therapies in patients with metastatic RCC (13, 14). These drugs greatly improved the survival rate of patients with metastatic RCC. However, cardiotoxicity cannot be ignored (15–17).
Hemocytopenia due to antineoplastic therapy is a common occurrence in clinic (18–21). Neutropenia is independently associated with septicemia (22, 23). In addition, the process of tumor metastasis may damage the immune system, resulting in a higher infection risk in cancer patients (24). In this study, patients with stage IV RCC had a markedly higher risk of death from septicemia, especially those who died within a year (SMR, 3.95; 95% CI, 3.05–5.04 for infections; SMR, 2.20; 95% CI, 1.83–2.62 for pneumonia and influenza). In our study, patients with stage IV disease were at a higher risk of suicide. This outcome is similar to that of Guo et al. (25).
In this study, we found that patients who underwent direct cancer surgery had a lower SMR than those who did not. It seems possible that these results are due to patients undergoing surgery having fewer comorbidity and better health conditions than those who did not.
Patients who were never married or in other marital statuses had a higher risk of all-cause death, kidney cancer-specific death, and other noncancer deaths than married patients. The fact that marriage provides social support may partly explain this finding (14, 26, 27).
However, this study has some limitations. First, our study design was retrospective, which inevitably resulted in a selection bias. We also performed our best to reduce bias. We used strict screening criteria to reduce the selection bias and use SMR to control for age, sex, and ethnic differences, rather than direct mortality to reduce confusion bias. Second, the SEER database lacks important information on treatment strategies and comorbid states, which may cause bias. Third, most of our participants were white, and whether our conclusion can be extended to other races, it still needs to be further verified. Finally, there may be potential misclassification of the cause of death in the SEER database. However, previous studies have shown that this variable is accurate in most situations (28).
Conclusions
In summary, this study provides the latest and most comprehensive assessment of the causes of death in patients with RCC. Causes of death varied according to patient demographics. Non-RCC causes of death account for more than 3/4 of RCC survivors among patients with stage I/II disease. Patients with stage IV are most likely to die of RCC; however, there is an increased risk of dying from septicemia, and suicide cannot be ignored. Therefore, attention should be paid not only to antineoplastic therapy, but also to the occurrence of other risks.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Author Contributions
(i) Conception and design: D-DY, W-KC, and C-YW. (ii) Administrative support: M-HZ and PL. (iii) Provision of study materials or patients: All authors. (iv) Collection and assembly of data: D-DY, W-KC, and C-YW. (v) Data analysis and interpretation: All authors. (vi) Manuscript writing: All authors. (vii) Final approval of manuscript: All authors.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.864132/full#supplementary-material
References
- 1. SEER . Cancer Stat Facts: Kidney and Renal Pelvis Cancer. Bethesda, MD: National Cancer Institute. (2022) Available at: https://seer.cancer.gov/statfacts/html/kidrp.html. [Google Scholar]
- 2. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer Treatment and Survivorship Statistics, 2019. CA Cancer J Clin (2019) 69(5):363–85. doi: 10.3322/caac.21565 [DOI] [PubMed] [Google Scholar]
- 3. Klaassen Z, Sayyid R, Wallis C. Lessons Learned From the Global Epidemiology of Kidney Cancer: A Refresher in Epidemiology 101. Eur Urol (2019) 75(1):85–7. doi: 10.1016/j.eururo.2018.09.035 [DOI] [PubMed] [Google Scholar]
- 4. Yang P, Zhang L, Hou X. Incidence of Suicide Among Adolescent and Young Adult Cancer Patients: A Population-Based Study. Cancer Cell Int (2021) 21(1):540–50. doi: 10.1186/s12935-021-02225-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Weiner AB, Li EV, Desai AS, Press DJ, Schaeffer EM. Cause of Death During Prostate Cancer Survivorship: A Contemporary, Us Population-Based Analysis. Cancer (2021) 127(16):2895–904. doi: 10.1002/cncr.33584 [DOI] [PubMed] [Google Scholar]
- 6. Moke DJ, Song Z, Liu L, Hamilton AS, Deapen D, Freyer DR. A Population-Based Analysis of 30-Year Mortality Among Five-Year Survivors of Adolescent and Young Adult Cancer: The Roles of Primary Cancer, Subsequent Malignancy, and Other Health Conditions. Cancers (Basel) (2021) 13(16):3956–71. doi: 10.3390/cancers13163956 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Sun S, Wang W, He C. Cardiovascular Mortality Risk Among Patients With Gastroenteropancreatic Neuroendocrine Neoplasms: A Registry-Based Analysis. Oxid Med Cell Longev (2021) 2021:9985814. doi: 10.1155/2021/9985814 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis LB. Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. J Clin Oncol (2015) 33(28):3105–15. doi: 10.1200/JCO.2014.60.3654 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Feng Y, Jin H, Guo K, Wasan HS, Ruan S, Chen C. Causes of Death After Colorectal Cancer Diagnosis: A Population-Based Study. Front Oncol (2021) 11:647179. doi: 10.3389/fonc.2021.647179 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Orskov B, Sorensen VR, Feldt-Rasmussen B, Strandgaard S. Changes in Causes of Death and Risk of Cancer in Danish Patients With Autosomal Dominant Polycystic Kidney Disease and End-Stage Renal Disease. Nephrol Dialysis Transplant (2011) 27(4):1607–13. doi: 10.1093/ndt/gfr467 [DOI] [PubMed] [Google Scholar]
- 11. Shao N, Wan F, Abudurexiti M, Wang J, Zhu Y, Ye D. Causes of Death and Conditional Survival of Renal Cell Carcinoma. Front Oncol (2019) 9:591. doi: 10.3389/fonc.2019.00591 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Wang Z, Yin Y, Wang J, Zhu Y, Li X, Zeng X. Standardized Incidence Rate, Risk and Survival Outcomes of Second Primary Malignancy Among Renal Cell Carcinoma Survivors: A Nested Case-Control Study. Front Oncol (2021) 11:716741. doi: 10.3389/fonc.2021.716741 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Pal S, Gong J, Mhatre S, Lin S, Surinach A, Ogale S, et al. Real-World Treatment Patterns and Adverse Events in Metastatic Renal Cell Carcinoma From a Large Us Claims Database. BMC Cancer (2019) 19(1):548. doi: 10.1186/s12885-019-5716-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Yuan R, Zhang C, Li Q, Ji M, He N. The Impact of Marital Status on Stage at Diagnosis and Survival of Female Patients With Breast and Gynecologic Cancers: A Meta-Analysis. Gynecol Oncol (2021) 162(3)778–787. doi: 10.1016/j.ygyno.2021.06.008 [DOI] [PubMed] [Google Scholar]
- 15. Di Lorenzo G, Autorino R, Bruni G, Cartenì G, Ricevuto E, Tudini M, et al. Cardiovascular Toxicity Following Sunitinib Therapy in Metastatic Renal Cell Carcinoma: A Multicenter Analysis. Ann Oncol (2009) 20(9):1535–42. doi: 10.1093/annonc/mdp025 [DOI] [PubMed] [Google Scholar]
- 16. Schmidinger M, Zielinski C, Vogl U, Bojic A, Bojic M, Schukro C, et al. Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol (2008) 26(32):5204–12. doi: 10.1200/jco.2007.15.6331 [DOI] [PubMed] [Google Scholar]
- 17. Chu T, Rupnick M, Kerkela R, Dallabrida S, Zurakowski D, Nguyen L, et al. Cardiotoxicity Associated With Tyrosine Kinase Inhibitor Sunitinib. Lancet (Lond Engl) (2007) 370(9604):2011–9. doi: 10.1016/s0140-6736(07)61865-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Burotto M, Edgerly M, Velarde M, Balasubramaniam S, Drabkin H, Gormaz J, et al. A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma. Oncologist (2017) 22(8):888–e84. doi: 10.1634/theoncologist.2017-0211 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Akaza H, Naito S, Ueno N, Aoki K, Houzawa H, Pitman Lowenthal S, et al. Real-World Use of Sunitinib in Japanese Patients With Advanced Renal Cell Carcinoma: Efficacy, Safety and Biomarker Analyses in 1689 Consecutive Patients. Jpn J Clin Oncol (2015) 45(6):576–83. doi: 10.1093/jjco/hyv045 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Rini B, Redman B, Garcia J, Burris H, Li S, Fandi A, et al. A Phase I/IiI Study of Lenalidomide in Combination With Sunitinib in Patients With Advanced or Metastatic Renal Cell Carcinoma. Ann Oncol (2014) 25(9):1794–9. doi: 10.1093/annonc/mdu212 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Weikert S, Kempkensteffen C, Busch J, Johannsen M, Grünwald V, Zimmermann K, et al. Sequential Mtor Inhibitor Treatment With Temsirolimus in Metastatic Renal Cell Carcinoma Following Failure of Vegf Receptor Tyrosine Kinase Inhibitors. World J Urol (2013) 31(4):805–9. doi: 10.1007/s00345-011-0676-1 [DOI] [PubMed] [Google Scholar]
- 22. Kochanek M, Schalk E, von Bergwelt-Baildon M, Beutel G, Buchheidt D, Hentrich M, et al. Management of Sepsis in Neutropenic Cancer Patients: 2018 Guidelines From the Infectious Diseases Working Party (Agiho) and Intensive Care Working Party (Ichop) of the German Society of Hematology and Medical Oncology (Dgho). Ann Hematol (2019) 98(5):1051–69. doi: 10.1007/s00277-019-03622-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Schreiber R, Old L, Smyth M. Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. Science (New York NY) (2011) 331(6024):1565–70. doi: 10.1126/science.1203486 [DOI] [PubMed] [Google Scholar]
- 24. Liyanage U, Moore T, Joo H, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients With Pancreas or Breast Adenocarcinoma. J Immunol (Baltimore Md 1950) (2002) 169(5):2756–61. doi: 10.4049/jimmunol.169.5.2756 [DOI] [PubMed] [Google Scholar]
- 25. Guo C, Zheng W, Zhu W, Yu S, Ding Y, Wu Q, et al. Risk Factors Associated With Suicide Among Kidney Cancer Patients: A Surveillance, Epidemiology, and End Results Analysis. Cancer Med (2019) 8(11):5386–96. doi: 10.1002/cam4.2400 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Wang H, Wang L, Kabirov I, Peng L, Chen G, Yang Y, et al. Impact of Marital Status on Renal Cancer Patient Survival. Oncotarget (2017) 8(41):70204–13. doi: 10.18632/oncotarget.19600 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Aizer A, Chen M, McCarthy E, Mendu M, Koo S, Wilhite T, et al. Marital Status and Survival in Patients With Cancer. J Clin Oncol (2013) 31(31):3869–76. doi: 10.1200/jco.2013.49.6489 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Kutikov A, Egleston BL, Wong Y-N, Uzzo RG. Evaluating Overall Survival and Competing Risks of Death in Patients With Localized Renal Cell Carcinoma Using a Comprehensive Nomogram. J Clin Oncol (2010) 28(2):311–7. doi: 10.1200/jco.2009.22.4816 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.